SynthesisClinical research in cardiology : official journal of the German Cardiac Society2019
Transcatheter aortic valve replacement for pure aortic valve regurgitation: "on-label" versus "off-label" use of TAVR devices.
Synthesis in Clinical research in cardiology : official journal of the German Cardiac Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Single arm meta-analysis of the J-Valve system for aortic regurgitation in Chinese populations.Frontiers in cardiovascular medicine · 2025Pooled it
- Transcatheter aortic valve replacement for aortic regurgitation: a systematic review and meta-analysis.ESC heart failure · 2024Pooled it
- Structural Valve Deterioration after Transcatheter Aortic Valve Implantation Using J-Valve: A Long-Term Follow-Up.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2020Trial
- Predictors for Improvement of Mitral Regurgitation in Patients With Pure Severe Aortic Regurgitation Undergoing Transcatheter Aortic Valve Replacement: Can We Kill Two Birds With One Stone?Reviews in cardiovascular medicine · 2026Article
- Simultaneous TAVR and EVAR for Severe Aortic Regurgitation With Giant Abdominal Aortic Aneurysm.JACC. Case reports · 2026Article
- Ross Procedure Renaissance: A Contemporary Review of Patient Selection, Technique, and Long-Term Outcomes in Adults.Journal of the American Heart Association · 2026Review
- Evaluating the Efficacy and Outcomes of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Low- to Intermediate-Risk Aortic Regurgitation Patients: A Comprehensive Clinical Comparison.Cardiology research and practice · 2026Article
- Efficacy and safety of transfemoral TAVR in pure aortic regurgitation patients: a single center study.Scientific reports · 2025Article
- MDCT evaluation of dynamic changes in aortic root parameters during the cardiac cycle in patients with aortic regurgitation.Scientific reports · 2025Article
- Eight-Year Clinical Outcomes of Transcatheter Aortic Valve Replacement with J-Valve System.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2025Article
- Multiple Valvular Heart Disease in the Transcatheter Era: A State-of-the-Art Review.Structural heart : the journal of the Heart Team · 2024Review
- Transcatheter Aortic Valve Implantation for Severe Chronic Aortic Regurgitation.Journal of clinical medicine · 2024Review
- Article
- Native aortic valve regurgitation and transcatheter aortic valve replacement: a word of caution or still too early?Indian journal of thoracic and cardiovascular surgery · 2024Article
- Predictors for new-onset conduction block in patients with pure native aortic regurgitation after transcatheter aortic valve replacement with a new-generation self-expanding valve (VitaFlow LibertyBMC cardiovascular disorders · 2024Article
- Successful Percutaneous Transcatheter Aortic Valve Replacement for Severe Aortic Regurgitation in a High-risk Patient with Cardiorenal Syndrome.US cardiology · 2024Article
- Contemporary Evaluation and Clinical Treatment Options for Aortic Regurgitation.Journal of cardiovascular development and disease · 2023Review
- Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center study.BMC cardiovascular disorders · 2023Article
- Cerebral ischemic injury after transcatheter aortic valve replacement in patients with pure aortic regurgitation.Journal of Zhejiang University. Science. B · 2023Article
- Transcatheter versus surgical aortic valve replacement in patients with aortic regurgitation: A propensity-matched analysis.Heliyon · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTranscatheter aortic valve replacement (TAVR) has become the mainstay of treatment for aortic stenosis in patients with high surgical risk. Pure aortic regurgitation (PAR) is considered a relative contraindication for TAVR; however, TAVR is increasingly performed in PAR patients with unfavorable risk profile. Herein, we aim to summarize available data on TAVR for PAR with special emphasis on "on-label" versus "off-label" TAVR devices. METHODS AND
resultsPubmed was searched for studies of patients undergoing TAVR for PAR. Primary outcome was 30 day-mortality. Pooled estimated event rates were calculated. Twelve studies including a total of 640 patients were identified until December 2017. Among these, 208 (33%) patients were treated with devices with CE-mark approval for PAR ("on-label"; JenaValve and J valve). Overall, the procedural success rate was 89.9% (95% CI 81.1-96.1%; I
conclusionBased on this summary of available observational data TAVR for PAR is feasible and safe in patients deemed inoperable. First-generation TAVR devices are associated with inferior outcome and should be avoided. The "on-label" use of PAR-certified TAVR devices is associated with a significantly higher procedural success rate and might be favorable compared to other second-generation devices.
Indexed as
Identifiers
30737532What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.